Homepage>Company>Media>Pharma News>2019>Transgene and AstraZeneca enter into a collaboration and exclusive license option agreement for innovative Invir.IOTM based armed oncolytic immunotherapies
Transgene and AstraZeneca enter into a collaboration and exclusive license option agreement for innovative Invir.IOTM based armed oncolytic immunotherapies